The Laboratoire d'ImmunoGénétique Moléculaire (LIGM) (Prof. Marie-Paule Lefranc and Prof. Gérard Lefranc), Université de Montpellier, UPR CNRS 1142, IGH, has been involved for more than 30 years in the genetics, structure, polymorphism and function of the immunoglobulins (IG) and T cell receptors (TR).
The scientific contribution of LIGM is shown by publications in international journals, communications, invitations to congresses and seminars, the isolation of 40 genomic probes. These probes, released by ATCC (American Type Culture Collection), JCRB (Japanese Cancer Research Resources Bank) and ICRF (Imperial Cancer Research Fund, Human Genetic Resource Centre), are used by many laboratories abroad, for fundamental research and clinical applications. Some of these probes are powerful tools in the characterisation of the B and T cells, the analysis of clonality in leukemias and lymphomas, and the therapeutics follow up (residual diseases). 134 genomic sequences have been sent to the EMBL/GenBank databases.
In 1989, LIGM started IMGT/LIGM-DB, the first specialised and integrated database on immunoglobulins (IG) and T cell receptors (TR). Since May 2000 and owing to the considerable expansion and success of IMGT®, the international ImMunoGeneTics information system®, the LIGM scientific activity has been mainly devoted to the IMGT® research and development.
IMGT®, founded in Montpellier in 1989 by Marie-Paule Lefranc (Université de Montpellier and CNRS) is the international reference in immunogenetics and immunoinformatics. IMGT® is specialized in the sequences, genes and structures of immunoglobulins (IG) or antibodies, T cell receptors (TR), major histocompatibility (MH) proteins of vertebrates, IgSF and MhSF superfamily proteins of vertebrates and invertebrates, fusion proteins for immunological applications (FPIA) and composite proteins for clinical applications (CPCA).
IMGT® consists of databases, interactive tools and Web resources. IMGT® is used by researchers in academic and pharmaceutical laboratories in multiple areas of research:
IMGT® is labeled Bioinformatics Platform RIO (2001), IBiSA (since 2007), Grand Plateau Technique for Research and Innovation Languedoc-Roussillon (since 2005), Cancéropôle Grand Sud-Ouest, ReNaBi, GDR CNRS: BiM, ACCITH, Labex MabImprove, Academic Institutional Member of the International Medical Informatics Association (IMIA) (since 2006). IMGT® is certified ISO 9001:2008.
All databases are available at http://www.imgt.org
All interactive on-line tools are available at http://www.imgt.org
All IMGT Web resources are available at http://www.imgt.org
IMGT® has been available on the Web since July 1995. IMGT® provides the biologists, researchers and clinicians with an easy to use and friendly interface. IMGT® has an exceptional response with more than 150,000 work sessions a month. Visitors are equally distributed between the European Union, the United States and the remaining world. IMGT/LIGM-DB data are also distributed by the HTTP or FTP and from many Sequence Retrieval System (SRS) sites. IMGT/LIGM-DB can be searched by BLAST or FASTA on different servers (EBI, Institut Pasteur, IGH...).
By its high quality and its easy data distribution, IMGT® has important implications in medical research (repertoires in autoimmune and infectious diseases, AIDS, leukemias, lymphomas, myelomas, allergy), veterinary research, functional genomics, genome diversity, genome evolution studies and comparative genomics of the adaptative immune system, biotechnology related to antibody engineering (combinatorial libraries, phage displays, single chain Fragment scFv, chimeric, humanized and human antibodies), diagnostic (detection and follow up of residual diseases), and therapeutical approaches (grafts, immunotherapy, vaccinology).
IMGT® has become the international reference in immunogenetics and immunoinformatics. At the cutting edge of immunology and bioinformatics, IMGT® is an invaluable integrated database for both fundamental, pharmaceutical, veterinary and clinical research.
IMGT initiator and coordinator: Marie-Paule Lefranc
Senior Member of the Institut Universitaire de France,
Professor Emeritus Université de Montpellier
IMGT, LIGM, IGH, UPR CNRS 1142, Montpellier (France)
The IMGT® information system is localized at the Laboratoire
d'ImmunoGénétique Moléculaire (LIGM), Institut de Génétique Humaine (IGH) of the
Centre National de la Recherche Scientifique (CNRS), Montpellier, France.
IMGT/HighV-QUEST HPC resources are hosted at the Centre Informatique National de l'Enseignement Supérieur (CINES).
The Internet access is provided by the french academic network RENATER.
The project of an integrated system in Immunogenetics has been started in 1989 by Marie-Paule Lefranc, Professor Université de Montpellier, CNRS, Montpellier, France.
A prototype of the ImMunoGeneTics information system was developed in France for Immunoglobulin and T cell receptor sequences (LIGM-DB) by the Laboratoire d'ImmunoGénétique Moléculaire (LIGM, CNRS, Université de Montpellier, Montpellier), in collaboration with the Centre National Universitaire Sud de Calcul (CNUSC, Montpellier, Sophie Creuzet and Denys Chaume) and the Laboratoire d'Informatique, de Robotique et de Micro-électronique de Montpellier (LIRMM, CNRS, Université de Montpellier, Montpellier, Isabelle Mougenot and Patrice Déhais).
In 1992 the database became truly european with the collaboration of EMBL (Rainer Fuchs),
IFG (Werner Müller), ICRF (Julia Bodmer) and the obtention of a EU European Union BIOMED1
IMGT/LIGM-DB is available on the Web server of CINES at Montpellier since July 1995. The first demonstration on-line was performed at the 9th International Congress of Immunology at San Francisco, USA (23-29 July 1995). IMGT/MHC-HLA, for human MH1 and MH2 (or HLA) sequences maintained by ANRI, London, is on the EBI server since December 1998.
IMGT®, the international ImMunoGeneTics information system®, enhanced its development through the European Community 5th PCRDT funding QLG2-2000-01287 (collaboration between LIGM, EMBL-EBI, Cancer Research UK, EUROGENTEC and BPRC), and then ImmunoGrid of the EU 6th PCRDT (IST-2004-028069). Since 2008, IMGT® is part of ELIXIR.